Trials / Recruiting
RecruitingNCT06036745
Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen
An Exploratory Single-Arm, Single-Center Study of Pembrolizumab in Combination With SOX Regimen for Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Shanghai Minimally Invasive Surgery Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
it is an an Exploratory Single-Arm, Single-Center Study of Pembrolizumab in Combination with SOX Regimen for Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab + SOX | Pembrolizumab 200mg, ivdrip, q3w; Oxaliplatin 135mg/m2, ivdrip，q3w; Trastuzumab 40 mg/m2，po bid，d1\~d14，q21d. Each cycle consists of three weeks, totaling eight cycles |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2023-07-01
- Completion
- 2026-07-01
- First posted
- 2023-09-14
- Last updated
- 2024-03-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06036745. Inclusion in this directory is not an endorsement.